Cigna exits ACA exchanges despite dramatic profit growth in Q1

Cigna reported first-quarter net income of $1.7 billion on $68.5 billion of revenue, both ahead of expectations, and raised 2026 adjusted EPS guidance to at least $30.35. The company is exiting ACA exchange plans by year-end and exploring a sale of EviCore, a restructuring that sharpens focus on pharmacy services and employer-sponsored plans but reflects shrinking exposure to lower-quality businesses. Cigna Healthcare’s medical loss ratio improved to 79.8% from 82.2% a year earlier, though Express Scripts pharmacy benefit operating income fell 28% as the business transitions to a new PBM model.

Analysis

This is less a one-off cleanup than a strategic de-risking of the earnings base. Exiting small, regulatorily noisy lines reduces headline volatility and management distraction, but it also makes the remaining book more levered to employer groups and pharmacy services just as the PBM model is being re-priced by regulators and clients. The near-term market read should be that the company is intentionally trading top-line breadth for a cleaner margin profile and a higher-quality multiple, which supports relative outperformance if execution stays intact.

The second-order winner is the broader managed-care peer set that still has scale in public exchanges or Medicare-related risk, because Cigna’s exit shrinks competitive intensity in the most stressed ACA geographies. That said, the beneficiaries are likely more local and regional carriers than the large nationals: they can selectively absorb members and reprice more efficiently if risk pools improve. The loser is not just Cigna’s remaining ACA competitors; hospitals and brokers in exit states face a scramble period that can temporarily lift administrative friction and churn, creating short-term enrollment slippage and potentially higher bad-debt leakage in Q4/Q1 transition windows.

The bigger catalyst is the PBM transition. Moving compensation away from spread/rebate economics should compress near-term economics, but it may also remove the biggest overhang on the stock because it reduces litigation/regulatory asymmetry and makes the business easier to underwrite as an admin-fee platform. The market may be underestimating how much this lowers the probability of an adverse FTC/state action cycle over the next 12 months, even if it trims earnings power in 2026-27.

The contrarian view is that the stock can rerate even if reported growth slows, because the multiple expansion from lower regulatory risk can outweigh modest EPS dilution. The main risk is that margin improvement in healthcare proves temporary if utilization normalizes upward once weather/flu noise fades, while the PBM transition causes a larger-than-expected revenue mix shift. That would create a 6-18 month window where the company looks cleaner but not obviously cheaper on forward earnings.

Key Decisions for Investors

• Long CI vs. short CVS on a 3-6 month horizon: CI has a cleaner portfolio reset and clearer regulatory de-risking, while CVS still carries more execution noise around legacy healthcare assets. Target 8-12% relative outperformance if the market continues to reward simplification.
• Buy CI call spreads 6-9 months out rather than outright stock if you want exposure to a rerating from lower regulatory risk. Best risk/reward is a moderate upside structure because the thesis is multiple expansion, not a major earnings inflection.
• Watch for a pullback in CI on any headline about EviCore sale terms; use weakness to accumulate if the business is sold at a reasonable multiple. A successful divestiture should remove a governance overhang and support a higher-quality earnings narrative.
• Avoid chasing CNC on this headline: if ACA pressure remains acute, the exit can still be interpreted as evidence of structural difficulty in the market. Better to wait for clearer beneficiary evidence in peer enrollment data before expressing a long.
• If you want a cleaner sector expression, consider a modest long CI / short managed-care basket that still has exchange or government-program exposure. The pair works best over 2-4 quarters, when portfolio simplification is more likely to matter than one-quarter medical cost noise.